Diabetes Therapeutics News

By B. Digon, K. Rother. Diabetes, 2002

1,364 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The metabolic syndrome. (2008, unknown): “Of note, the TRIPOD study showed that troglitazone could slow the progression to T2D in high-risk women with recent history of GDM (597).”
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. (2004, background): “In parallel, the DPP (8), the Study to Prevent (STOP)-NIDDM (19), and the Troglitazone in the Prevention of Diabetes (TRIPOD) (20) trials demonstrated that antidiabetic drugs were similarly more effective than stan- DIABETES CARE, VOLUME 27, NUMBER 1, JANUARY 2004 159 dard care alone.”
Gestational diabetes mellitus. (2005, background): “impaired glucose tolerance results in a reciprocal downregulation of insulin secretion (61), which in turn is associated with a reduction in the risk of diabetes and with preservation of β cell function (62).”
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) (2006, background): “Pharmacological agents such as metformin [1], troglitazone [5, 6] and acarbose [7] have also been found to be effective.”
Minireview: adiposity, inflammation, and atherogenesis. (2003, background): “The TRIPOD study suggested that an early PPAR ligand, troglitazone, prevented type 2 diabetes in a high-risk cohort (100).”